1-Methyl-4-(2-methylpropyl)piperidin-4-ol | 1178203-04-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methyl-4-(2-methylpropyl)piperidin-4-ol
• CAS: 1178203-04-7
• 化学式: C₁₀H₂₁NO
• 分子量: 171.28
• InChiKey: OPHMXSBZPMACNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2016191172A1

  公开（公告）日：2016-12-01

  Compounds of formula (I) that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公式(I)的化合物是成纤维细胞生长因子抑制剂（FGFR），因此可用于治疗可通过抑制FGFR治疗的疾病。还披露了包含此类化合物的药物组合物以及制备此类化合物的过程。
• IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
  申请人：Xu Yong

  公开号：US20120058997A1

  公开（公告）日：2012-03-08

  The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

  本发明提供了蛋白激酶抑制剂，包括以下结构（I）和（II）的咪唑[1,2-b]吡啶和吡唑[1,5-a]嘧啶化合物或其立体异构体、前药或药物可接受的盐，其中R、R1、R2和X如本文所定义。还公开了将其用于治疗癌症和其他Pim激酶相关疾病的组合物和方法。
• PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20140206711A1

  公开（公告）日：2014-07-24

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α 2B , α 1B or α 2A . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  这份披露涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。提供了包括这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。这些化合物可以结合并拮抗受体α2B、α1B或α2A。这些化合物可以用于治疗，例如，（i）降低血压和/或（ii）促进肾血流和/或（iii）降低或抑制钠重吸收，或者调节血糖水平，增加胰岛素分泌，并治疗对增加胰岛素产生反应的疾病或状况。这些化合物还可以用于治疗预计会对降低血压产生反应的疾病或状况。特别描述了使用这些化合物治疗心血管、肾脏障碍或2型糖尿病的用途。
• QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
  申请人：Principia Biopharma, Inc.

  公开号：US20160200725A1

  公开（公告）日：2016-07-14

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明公开了一种纤维母细胞生长因子抑制剂（FGFR），因此对于通过抑制FGFR可治疗的疾病具有用处的化合物。同时还公开了包含这种化合物的制药组合物以及制备这种化合物的方法。
• PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20150258075A1

  公开（公告）日：2015-09-17

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。所述化合物的制药组合物也提供，以及使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。该化合物可能结合并拮抗α2B、α1B或α2A受体。该化合物可能用于治疗，例如：（i）降低血压和/或（ii）促进肾血流和/或（iii）减少或抑制钠重吸收，或调节血糖水平，增加胰岛素分泌并治疗预计对胰岛素产生增加反应的疾病或情况。该化合物还可用于治疗预计对血压降低有反应的疾病或情况。特别描述了使用该化合物治疗心血管、肾脏疾病或2型糖尿病的用途。